

# Synthesis of the Nonpeptide Renin Inhibitor A-68064 and the ACE Inhibitor Methyl Enalaprilat from (5S)-2,3,5,6-Tetrahydro-5-alkyl-N-(tert-butyloxycarbonyl)-4H-1,4-oxazine-2-ones


William R. Baker\* and Stephen L. Condon

Pharmaceutical Products Division, Abbott Laboratories, One Abbott Park Road, Abbott Park, IL 60064

Key words: nonpeptide renin inhibitor; ACE inhibitor

**Abstract:** The nonpeptide renin inhibitor, A-68064, and the ACE inhibitor methyl enalaprilat were synthesized from (5S) 2,3,5,6-tetrahydro-5-benzyl-(butyl)-N-(tert-butyloxycarbonyl)-4H-1,4-oxazine-2-ones **7a** and **7b**, and (5S) 2,3,5,6-tetrahydro-5-methyl-N-(tert-butyloxycarbonyl)-4H-1,4-oxazine-2-one **12**, respectively.

We have recently identified a novel series of renin inhibitory compounds whose structure is typified by A-68064 (**1**).<sup>1</sup> These nonpeptide inhibitors possessed a novel (2S,4S)-3-aza-2,4-disubstituted glutaric acid moiety **2** at the P<sub>2</sub>/P<sub>3</sub> position of the molecule, a moiety also found in the ACE inhibitor, enalaprilat (**16**). We have developed




a general synthetic approach to the 3-aza-2,4-dialkyl glutaric acid structures **5** and **6** which depends on the stereoselective alkylation of (5S) 2,3,5,6-tetrahydro-5-benzyl or butyl-N-(tert-butyloxycarbonyl)-4H-1,4-oxazine-2-ones (**7a** and **b**).<sup>2</sup> The versatility of the approach relied on the intrinsic C<sub>2</sub> symmetry available to lactone **4** and complimentary synthetic protocols for the preparation of **5** and **6** from **3**. Thus, the hydroxyester **3**, available from **4** by hydrolysis of lactone **4** and esterification of the resulting acid, was oxidized to the carboxylic acid. Transformation of the carboxylic acid ester into the bisamide **5** was achieved by following a three step protocol; 1) amine (R<sub>2</sub>R<sub>3</sub>NH) coupling, 2) hydrolysis of the methyl ester, and 3) amine (R<sub>4</sub>R<sub>5</sub>NH) coupling. Reversal of the protocol (couple amine R<sub>4</sub>R<sub>5</sub>NH, methyl ester hydrolysis, and then couple amine R<sub>2</sub>R<sub>3</sub>NH) produced the isomeric bisamide **6** and interchanged the R and R<sub>1</sub> substituents. Application of both synthetic protocols for the synthesis of renin inhibitor, A-68064 (**1**) is shown in scheme 1. The methodology was also employed for the synthesis of the ACE inhibitor, methyl enalaprilat (**15**, scheme 2).

Alkylation of **7a** with *n*-butyl iodide, hydrolysis of the resulting dialkyl lactone (LiOH, aq. THF, 24 h, rt), and esterification with diazomethane gave hydroxy ester **8a** in 60% overall yield. A parallel series of reactions were performed on the butyl lactone **7b** to produce the hydroxy ester **8b** in 59% overall yield. Renin inhibitor, A-68064 (**1**) was prepared from both hydroxy esters **8a** and **8b** by the two protocols described. A two step oxidation (Swern oxidation followed by 1M KMnO<sub>4</sub>, pH 5-6, *t*-BuOH<sup>3</sup>) of alcohol **8a** was employed for the synthesis of the carboxylic acid. Coupling the crude acid with morpholine (EDC, HOBT, DMF, 18 h, -23 °C to rt) and hydrolysis of the methyl ester (LiOH, aq. dioxane, 24 h, rt) gave acid **9** in 26% overall yield from **8a**. All attempts to couple acid **9** with the amine diol **10**<sup>4</sup> using standard peptide coupling procedures failed. However, the coupling reaction was successfully performed by first forming the cyclic anhydride intermediate from acid **9** (9 eq. of oxalyl chloride, 2h, rt) and reacting the anhydride with amine **10** (0 °C to rt, 18 h) in CHCl<sub>3</sub>. Compound **1** was isolated as a white amorphous solid in 53% isolated yield.

The synthesis of inhibitor **1** from hydroxy ester **8b** was also accomplished. Oxidation of **8b** gave the carboxylic acid which was reacted with **10** via the cyclic anhydride intermediate to give **11** in 23% yield. Conversion of ester **11** to inhibitor **1** was completed in 29% overall yield by hydrolysis of the methyl ester (aq. LiOH dioxane, 18 h, rt) and coupling the resulting acid with morpholine (EDC, HOBT, DMF, 18h -23 °C to rt).

The <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for compound **1** obtained from both synthetic routes were identical.


Scheme 1



The synthesis of the ACE inhibitor methyl enalaprilat **15** was achieved in seven steps starting from (5S) 2,3,5,6-tetrahydro-5-methyl-N-(tert-butoxycarbonyl)-4H-1,4-oxazine-2-one (**12**, scheme 2). Alkylation of **12** with phenethyl iodide using the standard conditions gave lactone **13** in 29% isolated. The low yield of compound **13** was expected since phenethyl iodide is known to undergo a  $\beta$ -elimination side reaction to form styrene during alkylation reactions. Methyl ester **14** was obtained in 64% yield from **13** by the procedures previously described. The synthesis of methyl enalaprilat **15** was completed by coupling L-proline benzyl ester to acid **14** and cleavage of the benzyl ester by hydrogenolysis. Correlation of **15** to enalaprilat (**16**) was accomplished by reaction of **15** with diazomethane to give the dimethyl ester which was identical ( $^1\text{H}$  NMR,  $^{13}\text{C}$  NMR, and TLC) to a sample of dimethyl ester prepared from enalaprilat (**16**) and diazomethane.

In conclusion, (3S, 5S) 2,3,5,6-tetrahydro-3,5-dialkyl-N-(tert-butoxycarbonyl)-4H-1,4-oxazine-2-ones served as useful starting materials for the synthesis of nonpeptide renin and ACE inhibitors. The ring opened 1,4-oxazine-2-ones were transformed by two synthetic protocols into the bisamides **5** or **6**. Application of this methodology for structure-activity relationship (SAR) studies of nonpeptide renin inhibitors are underway and will be reported in due course.

Scheme 2



## References and Notes

1. Structure-activity relationship studies of nonpeptide renin inhibitors has been presented in preliminary form: Fung, A. K. L.; Baker, W. R.; Stein, H. H.; Kleinert, H. D.; Plattner, J. J.; Armiger, Y.-L.; Condon, S. L.; Cohen, J.; Egan, D. A.; Barlow, J. L.; Verburg, K. M.; Martin, D. L.; Young, G. A.; Polakowski, J. S.; Hutchins, C. W.; Donner, B. G.; Perun, T. J. Part II. Design, Synthesis and Biological Activity of Potent Nonpeptide Renin Inhibitors. *Abstracts of Papers*, 201st ACS National Meeting, Atlanta, GA; American Chemical Society, Washington, DC, 1991; MEDI 54. A full account of the SAR studies describing A-68034 analogs is in press, *Journal of Medicinal Chemistry*.
2. See the preceding article in this issue.
3. Abiko, A.; Roberts, J. C.; Takemasa, T.; Masamune, S. *Tetrahedron Lett.* **1986**, *27*, 4537-40.
4. For a synthesis of the amine diol **10** see the following article in this issue and references cited therein.

(Received in USA 15 October 1991; accepted 27 December 1991)